Gefitinib, a selective tyrosine kinase inhibitor of EGFR, induced a reduction in OCT4 and SOX2 levels in CAL‐27 and SCC‐15 cells, two human tongue squamous cell carcinoma cell lines. The gene discussed is SOX2; the disease is tongue squamous cell carcinoma.